In addition, benefiting from the FBLD strategy, recently reported Lp‐PLA2 inhibitors exhibit favorable physicochemical properties and PK profiles.34, 35 In terms of their clinical applications, although Lp‐PLA2 inhibitors failed to reduce the incidence of CVD events, they indeed showed significant therapeutic effects on microvascular diseases such as DR and AD. The gene discussed is PLA2G7; the disease is Alzheimer disease.